Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Hematology · Primary Immune Thrombocytopenia

Special Populations: Children and Pregnancy

At a Glance

In children, primary ITP often resolves within 6 to 12 months, so observation is common when bleeding is absent or mild. During pregnancy, coordinated care plans treatment and delivery platelet targets while monitoring the newborn for temporary low platelets.

While Primary ITP follows a general pattern, it behaves very differently in two specific groups: children and pregnant women. In these populations, the focus shifts from just managing a number to supporting natural recovery in children and ensuring a safe delivery for mothers and babies.

(Note: If this section does not apply to you, you can skip to the next page.)

ITP in Children: A Path to Natural Recovery

In children, ITP is often a sudden but temporary event. Unlike adults, where ITP frequently becomes chronic, approximately 75% to 80% of children will experience a spontaneous and complete recovery within 6 to 12 months [1][2].

The “Watch and Wait” Approach

Because childhood ITP is usually self-limiting, the current standard of care for children with no bleeding or only mild bruising is observation [3][4]. This means your child may not receive any medication even if their platelet count is very low.

  • Why observe? Research has shown that treating a child with medications like IVIG may raise the count temporarily, but it does not change whether the ITP eventually becomes chronic [5].
  • Safety: Programs that favor observation over medication have found no increase in serious bleeding or hospitalizations [3][6].
  • Predicting Recovery: Children diagnosed under the age of 5, and especially infants under 1 year old, often have a higher chance of a quick and permanent recovery [7][8].

When is Treatment Needed?

Doctors typically recommend active treatment if a child has significant “wet” bleeding (like blood in the mouth or persistent nosebleeds), or if treatment is considered for quality-of-life, trauma risk, access to care, or an upcoming procedure [9][10].

ITP in Pregnancy: Planning for Delivery

Managing ITP during pregnancy is focused on two main goals: maintaining a safe platelet count for the mother during delivery and monitoring the health of the baby [11]. This requires close coordination between your obstetrician, hematologist, and anesthesia team well before labor begins.

Red Flags to Watch For

Thrombocytopenia in pregnancy is not always ITP. It can be a sign of pregnancy-specific emergencies like preeclampsia or HELLP syndrome, or TTP. Seek immediate obstetric assessment if you experience a severe headache, vision changes, right upper abdominal pain, shortness of breath, or rapidly worsening blood pressure. Do not attribute these automatically to ITP.

Treatment Targets and Tools

Most pregnant women with ITP do not require treatment during the first two trimesters unless their count is extremely low or they are bleeding [12]. As delivery approaches, the targets change:

  • Delivery Thresholds: Delivery targets are often around 50,000, but vary by delivery type and bleeding history. For epidural or spinal anesthesia, many contemporary recommendations consider a count of approximately 70,000 reasonable in selected patients [12][13]. A count of 100,000 is not universally required, and the final decision rests with your obstetric, hematology, and anesthesia teams. Cesarean delivery should not be performed solely because of ITP.
  • First-Line Options: If treatment is needed, corticosteroids (like prednisone) or IVIG are the preferred choices because they have the most established safety records during pregnancy [11][14].

The Baby’s Platelets

It is important to know that the mother’s platelet count does not reliably predict the baby’s count [15][16]. However, a history of prior neonatal thrombocytopenia in an older sibling is informative. While most babies born to mothers with ITP have normal platelet counts, some may experience temporary low platelets [17][18].

  • Monitoring: Your baby’s blood is often tested from the umbilical cord at birth.
  • The “Nadir”: A baby’s platelet count may continue to drop for a few days after they are born. Some reach their lowest count (the nadir) between day 3 and day 5 of life [19][15]. Repeat testing is done according to the neonatal team’s specific protocol, rather than every infant requiring the exact same schedule.
  • Outcome: In the vast majority of cases, the baby’s low platelets are temporary and resolve on their own as the mother’s antibodies naturally clear the baby’s system.

Common questions in this guide

Why are many children with ITP watched instead of treated right away?
Childhood ITP is often temporary, and about 75% to 80% of children recover completely within 6 to 12 months. When a child has no bleeding or only mild bruising, observation can avoid medication that may raise the platelet count temporarily without changing the long-term chance of chronic ITP.
When might a child with ITP need active treatment?
Treatment may be considered if a child has significant bleeding from the mouth, persistent nosebleeds, or another important bleeding symptom. Doctors may also consider treatment for quality-of-life concerns, injury risk, difficulty reaching medical care, or an upcoming procedure.
What platelet count may be needed for delivery or an epidural during pregnancy?
A delivery platelet target is often around 50,000, but the appropriate level depends on the type of delivery and the person's bleeding history. For an epidural or spinal anesthetic, a count around 70,000 may be reasonable in selected patients; the obstetric, hematology, and anesthesia teams make the final decision, and a count of 100,000 is not universally required.
What treatments are commonly used for ITP during pregnancy?
If treatment is needed, corticosteroids such as prednisone or intravenous immunoglobulin are commonly preferred because they have the most established safety records during pregnancy. The decision depends on the platelet count, bleeding, stage of pregnancy, and delivery plan.
Can a baby have low platelets when the mother has ITP?
Yes, some babies born to mothers with ITP develop temporary low platelets, although most have normal counts. The mother's platelet count does not reliably predict the baby's count, so the newborn's blood is often tested at birth and may be checked again because the lowest count can occur around days 3 to 5.
What pregnancy symptoms require urgent assessment if I have ITP?
Severe headache, vision changes, right upper abdominal pain, shortness of breath, or rapidly worsening blood pressure need immediate obstetric assessment. Low platelets in pregnancy can also occur with conditions such as preeclampsia, HELLP syndrome, or TTP, so these symptoms should not automatically be attributed to ITP.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on primary thrombocytopenia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.In my child's case, what specific bleeding symptoms would change our approach from observation to active treatment?
  2. 2.If we choose to observe my child without medication, how often do we need to repeat blood tests to monitor their count?
  3. 3.For my pregnancy, what is the specific platelet threshold your anesthesiology team requires for me to receive an epidural or spinal anesthesia?
  4. 4.If I need treatment in my third trimester, will we start with oral steroids or IVIG, and what are the risks for the baby?
  5. 5.What is the specific monitoring plan for my baby's platelets after birth, and when will they have their first blood test?

References

References (19)
  1. 1

    Predictors of remission in children with newly diagnosed immune thrombocytopenia: Data from the Intercontinental Cooperative ITP Study Group Registry II participants.

    Bennett CM, Neunert C, Grace RF, et al.

    Pediatric blood & cancer 2018; (65(1)) doi:10.1002/pbc.26736.

    PMID: 28792679
  2. 2

    Advances in management of pediatric chronic immune thrombocytopenia: a narrative review.

    Lee JM

    Journal of Yeungnam medical science 2023; (40(3)):241-246 doi:10.12701/jyms.2022.00745.

    PMID: 36617702
  3. 3

    Multicenter initiative to standardize management of pediatric immune thrombocytopenia improves adherence to guidelines.

    Gunn E, Angulo PA, Badawy SM, et al.

    Blood advances 2026; (10(9)):3304-3312 doi:10.1182/bloodadvances.2025018690.

    PMID: 41643186
  4. 4

    Multicenter Cohort Study Comparing U.S. Management of Inpatient Pediatric Immune Thrombocytopenia to Current Treatment Guidelines.

    Witmer CM, Lambert MP, O'Brien SH, Neunert C

    Pediatric blood & cancer 2016; (63(7)):1227-31 doi:10.1002/pbc.25961.

    PMID: 26929009
  5. 5

    Intravenous immunoglobulin vs observation in childhood immune thrombocytopenia: a randomized controlled trial.

    Heitink-Pollé KMJ, Uiterwaal CSPM, Porcelijn L, et al.

    Blood 2018; (132(9)):883-891 doi:10.1182/blood-2018-02-830844.

    PMID: 29945954
  6. 6

    Utilization of an ITP quality improvement pathway improves adherence to management guidelines.

    Harris EM, Hillier K, Nolan M, et al.

    Pediatric blood & cancer 2023; (70(3)):e30074 doi:10.1002/pbc.30074.

    PMID: 36518083
  7. 7

    Predictive factors for resolution of childhood immune thrombocytopenia: Experience from a single tertiary center in Thailand.

    Chotsampancharoen T, Sripornsawan P, Duangchoo S, et al.

    Pediatric blood & cancer 2017; (64(1)):128-134 doi:10.1002/pbc.26178.

    PMID: 27571705
  8. 8

    High Remission Rate of Chronic Immune Thrombocytopenia in Children: Result of 20-Year Follow-Up.

    Kim CY, Lee EH, Yoon HS

    Yonsei medical journal 2016; (57(1)):127-31 doi:10.3349/ymj.2016.57.1.127.

    PMID: 26632392
  9. 9

    [Management of pediatric immune thrombocytopenia].

    Mori M

    [Rinsho ketsueki] The Japanese journal of clinical hematology 2024; (65(9)):1209-1215 doi:10.11406/rinketsu.65.1209.

    PMID: 39358279
  10. 10

    Advances in Diagnosis and Treatments for Immune Thrombocytopenia.

    Nomura S

    Clinical medicine insights. Blood disorders 2016; (9()):15-22 doi:10.4137/CMBD.S39643.

    PMID: 27441004
  11. 11

    Immune thrombocytopenia and pregnancy: challenges and opportunities in diagnosis and management.

    Beltrami-Moreira M, Sharma A, Bussel JB

    Expert review of hematology 2024; (17(9)):595-607 doi:10.1080/17474086.2024.2385481.

    PMID: 39105265
  12. 12

    Treatment options for immune thrombocytopenia (ITP) in pregnancy and postpartum.

    Merz LE, Fogerty AE

    Expert opinion on pharmacotherapy 2025; (26(13)):1441-1449 doi:10.1080/14656566.2025.2557448.

    PMID: 40900606
  13. 13

    Efficacy of treatment immune thrombocytopenic purpura in pregnancy with corticosteroids and intravenous immunoglobulin: a prospective follow-up of suggested practice.

    Wegnelius G, Bremme K, Lindqvist PG,

    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2018; (29(2)):141-147 doi:10.1097/MBC.0000000000000683.

    PMID: 29324461
  14. 14

    Managing ITP and thrombocytopenia in pregnancy.

    Eslick R, McLintock C

    Platelets 2020; (31(3)):300-306 doi:10.1080/09537104.2019.1640870.

    PMID: 31296105
  15. 15

    Is it possible to predict morbidities in neonates born to mothers with immune thrombocytopenic purpura?: A retrospective cross-sectional study.

    Aslan MT, İnce Z, Bilgin L, et al.

    Medicine 2024; (103(25)):e38587 doi:10.1097/MD.0000000000038587.

    PMID: 38905433
  16. 16

    Neonatal Outcomes of Pregnancy with Immune Thrombocytopenia.

    Melekoğlu NA, Bay A, Aktekin EH, et al.

    Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion 2017; (33(2)):211-215 doi:10.1007/s12288-016-0708-5.

    PMID: 28596653
  17. 17

    Immune Thrombocytopenic Purpura and Maternal and Neonatal Outcomes During Pregnancy: A Systematic Review and Meta-Analysis.

    Zhang H, Shi L, Shang H, Yang H

    American journal of reproductive immunology (New York, N.Y. : 1989) 2024; (92(5)):e70008 doi:10.1111/aji.70008.

    PMID: 39498982
  18. 18

    A meta-analysis of neonatal outcomes in pregnant women with immune thrombocytopenic purpura.

    Luo H, Li D, Gao F, et al.

    The journal of obstetrics and gynaecology research 2021; (47(9)):2941-2953 doi:10.1111/jog.14890.

    PMID: 34137128
  19. 19

    Corticosteroids compared with intravenous immunoglobulin for the treatment of immune thrombocytopenia in pregnancy.

    Sun D, Shehata N, Ye XY, et al.

    Blood 2016; (128(10)):1329-35 doi:10.1182/blood-2016-04-710285.

    PMID: 27402971

This page is for informational purposes only and does not constitute medical advice. Your hematology, obstetric, anesthesia, and pediatric teams should tailor bleeding precautions, treatment, delivery planning, and newborn monitoring to your situation.